基于临床维度与2型糖尿病全基因组多基因风险评分评估胃肠道疾病风险:一项基于人群的队列研究
该研究纳入374,125名基线无胃肠道疾病的参与者,其中19,719名(5.27%)患有2型糖尿病,中位随访12.0年。2型糖尿病与多种胃肠道疾病风险升高相关,包括胃炎和十二指肠炎(HR 1.58)、消化性溃疡(HR 1.56)、非酒精性脂肪性肝病(HR 2.46)、肝硬化(HR 2.92)等。作者建议对2型糖尿病患者进行胃肠道疾病的早期发现和预防。
要点
- 2型糖尿病与胃炎和十二指肠炎风险升高相关(HR 1.58,95%CI 1.51-1.65)。
- 2型糖尿病与非酒精性脂肪性肝病风险升高相关(HR 2.46,95%CI 2.25-2.69)。
- 2型糖尿病与肝硬化风险升高相关(HR 2.92,95%CI 2.58-3.30)。
核心结论
- 在这项大型队列研究中,2型糖尿病与多种胃肠道结局风险升高相关;作者建议对2型糖尿病患者进行胃肠道疾病的早期发现和预防。
研究设计与样本
- 基于人群的队列研究,纳入374,125名基线无胃肠道疾病的参与者,其中19,719名(5.27%)患有2型糖尿病,通过链接多种医疗记录随访记录胃肠道疾病诊断;采用多因素Cox模型估计风险比(HR)和置信区间(CI),采用Logistic模型检验多基因风险评分(PRS)与临床胃肠道表型的关联。
主要发现
- 中位随访12.0年期间观察到15种新发胃肠道疾病;与无糖尿病者相比,2型糖尿病患者的胃炎和十二指肠炎风险升高(HR 1.58,95%CI 1.51-1.65),消化性溃疡风险升高(HR 1.56,95%CI 1.43-1.71),憩室病风险升高(HR 1.19,95%CI 1.14-1.24),胰腺炎风险升高(HR 1.45,95%CI 1.24-1.71),非酒精性脂肪性肝病风险升高(HR 2.46,95%CI 2.25-2.69),肝硬化风险升高(HR 2.92,95%CI 2.58-3.30),胆道疾病风险升高(HR 1.18,95%CI 1.10-1.26),胃肠道道癌症风险升高(HR 1.28,95%CI 1.17-1.40),肝胆胰癌症风险升高(HR 2.32,95%CI 2.01-2.67);还观察到2型糖尿病PRS与胃炎、十二指肠炎和非酒精性脂肪性肝病呈正相关。
关键数值与推荐
- 与无糖尿病者相比,2型糖尿病患者的胃炎和十二指肠炎风险升高(HR 1.58,95%CI 1.51-1.65)。
- 与无糖尿病者相比,2型糖尿病患者的消化性溃疡风险升高(HR 1.56,95%CI 1.43-1.71)。
- 与无糖尿病者相比,2型糖尿病患者的憩室病风险升高(HR 1.19,95%CI 1.14-1.24)。
- 与无糖尿病者相比,2型糖尿病患者的胰腺炎风险升高(HR 1.45,95%CI 1.24-1.71)。
- 与无糖尿病者相比,2型糖尿病患者的非酒精性脂肪性肝病风险升高(HR 2.46,95%CI 2.25-2.69)。
临床怎么用
- 作者建议对2型糖尿病患者进行胃肠道疾病的早期发现和预防。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to evaluate whether individuals with type 2 diabetes (T2D) were at higher risk of developing a wide range of gastrointestinal diseases based on a population-based cohort study. RESEARCH DESIGN AND METHODS: This study included 374,125 participants free of gastrointestinal disorders at baseline; of them, 19,719 (5.27%) with T2D were followed-up by linking to multiple medical records to record gastrointestinal disease diagnoses. Multivariable Cox models were used to estimate the hazard ratios (HRs) and CIs. Logistic models were used to examine the associations between polygenic risk scores (PRS) and clinical gastrointestinal phenotypes. RESULTS: During a median follow-up of 12.0 years, we observed the new onset of 15 gastrointestinal diseases. Compared with nondiabetes, participants with T2D had an increased risk of gastritis and duodenitis (HR 1.58, 95% CI 1.51-1.65), peptic ulcer (HR 1.56, 95% CI 1.43-1.71), diverticular disease (HR 1.19, 95% CI 1.14-1.24), pancreatitis (HR 1.45, 95% CI 1.24-1.71), nonalcoholic fatty liver disease (HR 2.46, 95% CI 2.25-2.69), liver cirrhosis (HR 2.92, 95% CI 2.58-3.30), biliary disease (HR 1.18, 95% CI 1.10-1.26), gastrointestinal tract cancers (HR 1.28, 95% CI 1.17-1.40), and hepatobiliary and pancreatic cancer (HR 2.32, 95% CI 2.01-2.67). Positive associations of PRS of T2D with gastritis, duodenitis, and nonalcoholic fatty liver disease were also observed. CONCLUSIONS: In this large cohort study, we found that T2D was associated with increased risks of a wide range of gastrointestinal outcomes. We suggest the importance of early detection and prevention of gastrointestinal disorders among patients with T2D.
引用
- Fu T, Sun Y, Lu S, et al. Risk Assessment for Gastrointestinal Diseases via Clinical Dimension and Genome-Wide Polygenic Risk Scores of Type 2 Diabetes: A Population-Based Cohort Study. Diabetes Care. 2024. PMID: 38166334. doi:10.2337/dc23-0978
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。